325 related articles for article (PubMed ID: 16313796)
21. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
22. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
23. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers].
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):741-4. PubMed ID: 16255879
[TBL] [Abstract][Full Text] [Related]
24. [Early detection of pancreatic cancer by serum markers].
Nakae Y; Naruse S; Shibata T; Kitagawa M; Kondo T; Hayakawa T; Kuno N; Kurimoto K
Rinsho Byori; 1994 Feb; 42(2):139-42. PubMed ID: 7511183
[TBL] [Abstract][Full Text] [Related]
25. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
26. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
Chen SB
Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
[TBL] [Abstract][Full Text] [Related]
27. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
28. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
29. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
30. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of non-invasive diagnostic tests in detecting cancer of the pancreas.
Wang JY; Chen FZ; Yang YZ
Chin Med J (Engl); 1990 Oct; 103(10):817-20. PubMed ID: 2125254
[TBL] [Abstract][Full Text] [Related]
32. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
33. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder.
Shukla VK; Gurubachan ; Sharma D; Dixit VK; Usha
Trop Gastroenterol; 2006; 27(4):160-5. PubMed ID: 17542293
[TBL] [Abstract][Full Text] [Related]
35. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
[TBL] [Abstract][Full Text] [Related]
36. Endoscopic ultrasonography versus helical CT in diagnosis and staging of pancreatic cancer.
Jemaa Y; Houissa F; Trabelsi S; Moussa A; Belhouchet H; Mouelhi L; Bouraoui M; Bouzaidi S; Debbeche R; Ben Yedder J; Salem M; Najjar T
Tunis Med; 2008 Apr; 86(4):346-9. PubMed ID: 19476136
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy.
Nakaizumi A; Uehara H; Takenaka A; Uedo N; Sakai N; Yano H; Ohigashi H; Ishikawa O; Ishiguro S; Sugano K; Tatsuta M
Hepatogastroenterology; 1999; 46(25):31-7. PubMed ID: 10228761
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
Lundin J; Roberts PJ; Kuusela P; Haglund C
Anticancer Res; 1995; 15(5B):2181-6. PubMed ID: 8572621
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic accuracy of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the detection of pancreatic cancer in patients with jaundice or cholestasis.
Pasanen P; Partanen K; Pikkarainen P; Alhava E; Pirinen A; Janatuinen E
In Vivo; 1992; 6(3):297-301. PubMed ID: 1391698
[TBL] [Abstract][Full Text] [Related]
40. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions.
Cwik G; Wallner G; Skoczylas T; Krzyzanowski M; Ciechainski A; Madro P
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):213-8. PubMed ID: 16146081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
